- Home
- CRSR vs PHAT Comparison
CRSR vs PHAT Comparison
Compare CRSR & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRSR | PHAT |
|---|---|---|
| Founded | 1994 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 986.3M | 942.6M |
| IPO Year | 2020 | 2019 |
Fundamental Metrics
Financial Performance| Metric | CRSR | PHAT |
|---|---|---|
| Price | $6.84 | $14.36 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 6 |
| Target Price | $9.94 | ★ $17.33 |
| AVG Volume (30 Days) | ★ 1.1M | 828.8K |
| Earning Date | 11-04-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,449,248,000.00 | $147,190,000.00 |
| Revenue This Year | $12.96 | $218.59 |
| Revenue Next Year | $9.28 | $84.38 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 9.79 | ★ 460.30 |
| 52 Week Low | $5.35 | $2.21 |
| 52 Week High | $13.02 | $16.27 |
Technical Indicators
Market Signals| Indicator | CRSR | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 53.46 | 49.05 |
| Support Level | $6.47 | $14.12 |
| Resistance Level | $6.84 | $16.27 |
| Average True Range (ATR) | 0.32 | 0.72 |
| MACD | 0.17 | -0.12 |
| Stochastic Oscillator | 94.03 | 8.39 |
Price Performance
Historical ComparisonAbout CRSR Corsair Gaming Inc.
Corsair Gaming Inc is engaged in the business of providing high-performance gear for gamers and content creators. The product portfolio includes Cases, Keyboards, Mice, Headsets, Power Supplies, Gaming Computers, Gaming Chairs, Mousepads, and other related products. The company operates in two segments namely, Gamer and Creator peripherals, which is the key revenue-generating segment; and Gaming Components and Systems. Geographically, the group derives revenue from the Americas, Europe and the Middle East, and the Asia Pacific.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.